Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Digoxin (12β-Hydroxydigitoxin; Dixina; HSDB-214; Novodigal; Lanoxin PG; SK-Digoxin; Cardiogoxin) is a sodium-potassium pump inhibitor and a cardiotonic glycoside that has been approved for use in the treatment of various heart conditions such as arrhythmia and heart failure. Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. Digoxin is taken by mouth or by injection into a vein. Digoxin was first isolated in 1930 from the foxglove plant, Digitalis lanata. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.
ln Vitro |
Digoxin is a sodium-potassium ATPase that has a negative Z-score of -26.67, which suggests that CHIKV infection is related to sodium-potassium ATPase. Digoxin treatment of U-2 OS cells led to a dose-reduced CHIKV infection, with a half-maximum effective concentration (EC50) of 48.8 nM, in comparison to DMSO-treated cells. With EC50s of 43.9 nM and 67.3, respectively, digoxin administration also decreased CHIKV infection in primary human synovial fibroblasts (HSF) and Vero African green monkey kidney cells. In these cell types, digoxin therapy greatly decreased CHIKV infection. Following infection, the EC50 of digoxin in ST2 cells was 16.2 μM, while in C2C12 cells it was 23.2 μM. These values were 330 and 475 times higher, respectively, than the EC50 of digoxin in U-2 OS cells. After treating these cells for 24 hours with 1 μM digoxin—a dosage that is 20 times the digoxin EC50—the CHIKV antiviral activity in these cells showed very modest impairments in cell viability [1].
|
---|---|
References |
[1]. Ashbrook AW, et al. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection. MBio. 2016 May 24;7(3). pii: e00693-16
|
Molecular Formula |
C41H64O14
|
|
---|---|---|
Molecular Weight |
780.94
|
|
CAS # |
20830-75-5
|
|
SMILES |
O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O[C@@](O[C@H](C)[C@H]3O[C@@](O[C@H](C)[C@H]4O[C@@](O[C@H](C)[C@H]5O)([H])C[C@@H]5O)([H])C[C@@H]4O)([H])C[C@@H]3O)C1)C)([H])[C@]2([H])C[C@H]6O)(CC[C@@H]7C(CO8)=CC8=O)[C@]67C
|
|
InChi Key |
LTMHDMANZUZIPE-PUGKRICDSA-N
|
|
InChi Code |
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
|
|
Chemical Name |
4-((3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-(((2R,4S,5S,6R)-5-(((2S,4S,5S,6R)-5-(((2S,4S,5S,6R)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2805 mL | 6.4025 mL | 12.8051 mL | |
5 mM | 0.2561 mL | 1.2805 mL | 2.5610 mL | |
10 mM | 0.1281 mL | 0.6403 mL | 1.2805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.